MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers

Investigative Radiology

Volumn 33, Issue 10, 1998, Pages 717-722

  Martí Bonmatí, Luis ^a   Lonjedo, Elena ^a   Poyatos, Cecilio ^a   Casillas, Carlos ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Cirrhosis of the liver; Contrast agents; Liver; Magnetic resonance

Indexed keywords

ASPARTATE AMINOTRANSFERASE; MANGAFODIPIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; LIVER PARENCHYMA; LIVER REGENERATION; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

EID: 0342368620     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199810000-00001     Document Type: Article

References (14)

1. Blomley MJK, Coulden R, Dawson P, et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 1995;19:424-433.
2. Martí-Bonmatí L, Talens A, del Olmo J, et al. MR imaging in chronic hepatitis and cirrhosis with histologic correlation. Radiology 1993; 88:37-41.
3. Martí-Bonmatí L, Masiá L, Casillas C, Ronchera-Oms C, Torrijo C. Differentiation of healthy from cirrhotic livers: Evaluation of parametric images after contrast administration in magnetic resonance imaging. Invest Radiol 1996;31:768-773.
4. Miles KA, Hayball MP, Dixon AK. Functional images of hepatic perfusion obtained with dynamic CT. Radiology 1993;188:405-411.
5. Torres CG, Lundby B, Tufte Sterud A, McGill S, Gordon PB, Strand Bjerknes H. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 1997;38:631-637.
6. Wang C, Gordon PB, Hustvedt SO, et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 1997;38:665-676.
7. Elizondo G. Freta CJ, Stark DD, et al. Preclinical evaluation of MnDPDP: New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991;178:73-78.
8. Lim KO, Stark DD, Leese PT, Pfefferbaum SM, Quay SC. Hepatobiliary MR imaging: First human experience with MnDPDP. Radiology 1991;178:79-82.
9. Murakami T, Baron RL, Federle MP, et al. Cirrhosis of the liver: MR imaging with Mangafodipir trisodium (Mn-DPDP). Radiology 1996;198:567-572.
10. Sidhu MK, Muller HH, Aggeler J, Jones AL, Young SW. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Invest Radiol 1993;28:903-910.
11. Tanimoto A, Kreft BP, Baba Y, et al. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. JMRI 1993;3:786-793.
12. Coley BD, Mattrey RF, Baker KG, Peterson T, Burgan AR. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP. JMRI 1995;5:11-16.
13. Marchal GM, Ni Y, Yu J, Lodemann KP, Baert AL. Mn-DPDP enhanced MRI in experimental bile duct obstruction. J Comput Assist Tomogr 1993;17:290-296.
14. Liou J, Lee JK, Borrello JA, Brown JJ. Differentiation of hepatomas from nonhepatomatous masses: Use of MnDPDP-enhanced MR images. Magn Reson Imaging 1994;12:71-79.